Saturday 17 October 2026
Export SOPH’s income statement to Excel — free account
SOPHiA GENETICS SA
SOPH Healthcare Health Information Services
SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
6.73
0.56
−7.68%
Follow SOPH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.40 | 4.08 | 4.34 | 4.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(36.70) | (38.77) | (23.29) | (55.39) | |
P/B ratio |
5.32 | 6.69 | 7.71 | 5.13 | |
Price to Tangible BV |
12.41 | 28.03 | 35.70 | 9.07 | |
EV/Sales |
3.96 | 3.81 | 4.14 | 4.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.55) | (8.20) | (8.35) | (9.26) | |
EV/FCF |
(7.44) | (8.04) | (8.04) | (8.91) | |
Quick Ratio |
2.44 | 1.69 | 1.71 | 2.38 | |
Current Ratio |
2.80 | 1.96 | 2.06 | 2.69 | |
Net Debt/EBITDA |
2.20 | 1.40 | 1.21 | 3.48 | |
Debt/Assets |
29.11% | 29.28% | 30.47% | 24.20% | |
Debt/Equity |
0.78 | 1.01 | 1.05 | 0.58 | |
Asset Turnover |
0.43 | 0.49 | 0.53 | 0.46 | |
Operating CF/Net income |
0.44 | 0.42 | 0.78 | 0.34 | |
Capex/Depreciation |
(0.10) | (0.09) | (0.33) | (0.05) | |
Interest Coverage |
(10.74) | (11.07) | (10.37) | (12.38) | |
Research and Development Expense of Revenue |
41.45% | 39.33% | 43.62% | 37.46% | |
Selling, General and Administrative Expense of Revenue |
115.91% | 113.57% | 104.08% | 113.20% | |
Intangible Assets out of Total Assets |
0.21 | 0.22 | 0.23 | 0.18 | |
Share Based Compensation of Revenue |
21.30% | 17.82% | 15.28% | 19.27% | |
Graham Net Nets |
0.00 | (0.05) | (0.04) | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.59%) | (25.12%) | (23.90%) | (19.93%) | |
Free Cash Flow Yield |
(12.10%) | (11.61%) | (11.87%) | (9.69%) | |
Revenue per Share |
0.29 | 0.32 | 0.30 | 0.32 | |
Operating CF per Share |
(0.13) | (0.12) | (0.21) | (0.10) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.12) | (0.23) | (0.11) | |
Cash per Share |
1.20 | 1.04 | 0.92 | 1.46 | |
Shareholders Equity per Share |
0.90 | 0.70 | 0.64 | 1.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.90 | 0.70 | 0.64 | 1.13 | |
Free Cash Flow |
(9.03) | (8.36) | (16.03) | (7.84) | |
Working Capital |
66.55 | 48.55 | 49.22 | 86.21 | |
Capital Expenditures |
(0.24) | (0.22) | (0.91) | (0.15) | |
Net Current Asset Value |
0.71 | (16.81) | (15.50) | 22.05 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.04 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.11 | 11.22 | 12.50 | 11.81 | |
Average Payables |
5.96 | 7.09 | 8.64 | 9.82 | |
Average Inventory |
6.58 | 6.11 | 6.07 | 6.65 | |
Average Assets |
170.53 | 159.17 | 151.86 | 187.99 | |
Average Common Equity |
87.10 | 71.82 | 65.65 | 79.91 |
Columns are period end dates